A detailed history of Ensign Peak Advisors, Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 59,650 shares of IBRX stock, worth $153,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,650
Previous 59,650 -0.0%
Holding current value
$153,300
Previous $376,000 41.22%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$3.23 - $6.17 $192,669 - $368,040
59,650 New
59,650 $320,000
Q3 2022

Nov 14, 2022

SELL
$3.65 - $6.43 $154,979 - $273,017
-42,460 Reduced 42.4%
57,690 $287,000
Q2 2022

Aug 12, 2022

BUY
$2.68 - $6.14 $212,524 - $486,902
79,300 Added 380.34%
100,150 $373,000
Q1 2022

May 16, 2022

BUY
$5.05 - $7.53 $82,264 - $122,663
16,290 Added 357.24%
20,850 $117,000
Q4 2021

Feb 11, 2022

BUY
$5.67 - $10.18 $25,855 - $46,420
4,560 New
4,560 $28,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.03B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.